Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis.

AUGUSTOVSKI F,; SOTO N,; CAPORALE J,; GONZALEZ L,; GIBBONS L,; CIAPPONI A.

BREAST CANCER RESEARCH AND TREATMENT

SPRINGER

Lugar: Berlin; Año: 2015

0167-6806

Risk stratification based on results provided by a 21-gene assay (Oncotype DX ®) in early stagebreast cancer can help to optimize hormone therapy (HT) +/- chemotherapy (CT) decisions, bystratifying women according to recurrence risk and benefit-risk balance of treatments. HTAbodies as NICE recommends it for intermediate risk women. Previous reviews of decision impactdid not provide data on both overall and net decision impact regarding use of CT in this group